HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Greatview Aseptic Packaging (468.HK) Update - Some New Information Worth the Attention

Pre-IPO China Resources Beverage (PHIP Updates) - Some Points Worth the Attention

China TCM (570.HK) Privatization Update - The Long Stop Date to Extend or Not?

Equity Capital Markets

China Resources Beverage / Equity Capital Markets

<ul>
<li>The whole industry has entered a medium to low-speed growth stage, and the industry's future growth rate will remain single-digit growth. So, CR Beverage's future performance decline is inevitable.</li>
<li>Due to serious homogenization/competition of packaged drinking water market, there’s not much room for innovation/iteration. CR Beverage's sales-driven model is hard to bring “new story” to break through the dilemma. </li>
<li>CR Beverage is clearly inferior to Nongfu Spring. Its valuation should be lower than Nongfu Spring. We think reasonable valuation of CR Beverage is about US$4 billion (or lower).</li>
</ul>


The whole industry has entered a medium to low-speed growth stage, and the industry's future growth rate will remain single-digit growth. So, CR Beverage's future performance decline is inevitable.
Due to serious homogenization/competition of packaged drinking water market, there’s not much room for innovation/iteration. CR Beverage's sales-driven model is hard to bring “new story” to break through the dilemma. 
CR Beverage is clearly inferior to Nongfu Spring. Its valuation should be lower than Nongfu Spring. We think reasonable valuation of CR Beverage is about US$4 billion (or lower).


Pre-IPO China Resources Beverage - Due to the Pain Points, High Valuation Is Not Justified